4-Year Results from the Pivotal Phase 2 PACE Trial: Efficacy and Safety in Heavily Pretreated Leukemia Patients

Ponatinib, an approved tyrosine kinase inhibitor, is potently active against native and resistant BCR-ABL, including BCR-ABL1T315I.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Jorge Cortes, Javier Pinilla-Ibarz, Philipp le Coutre, Ronald Paquette, Charles Chuah, Franck Nicolini, Jane Apperley, H. Jean Khoury, Moshe Talpaz, Michele Baccarani, Stephanie Lustgarten, Frank G. Haluska, Fran çois Guilhot, Michael W. Deininger, Andre Source Type: research